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Signaling networks in hepatic oval cell activation
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Portland, OR 97239, USA
b Department of Molecular and Medical Genetics, Oregon Health Science University, 3181 SW Sam Jackson Park Road,
Mail Code L321, Portland, OR 97239, USAReceived 8 November 2007; received in revised form 2 January 2008; accepted 12 January 2008Abstract Oval cells are hypothesized to be the progeny of intrahepatic stem cells, also referred to as adult liver stem cells.
The mechanisms by which these cells are activated to proliferate and differentiate during liver regeneration is important for the
development of new therapies to treat liver disease. Oval cell activation is the first step in progenitor-dependent liver
regeneration in response to certain types of injury. This review describes what is currently known about the factors involved in
oval cell activation, proliferation, migration, and differentiation.
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pithelial cell types, including hepatocytes, bile duct epithe-
lium, endothelium, Kupffer cells, and myofibroblasts (stellate
cells). Most hepatic injuries—such as surgical partial hepa-
tectomy—result in a progenitor-independent proliferative
response of preexisting mature cells. However, other forms
of liver damage, particularly those that block hepatocyte
replication, can induce progenitor-dependent liver regenera-
tion. This process involves the emergence of a new epithelial
cell type, not present in normal liver, termed “hepatic oval
cell.” After their initial activation, oval cells proliferate,
migrate, and differentiate into either hepatocytes or biliary
cells (Fig. 1). Although in vivo lineage tracing studies have not
been reported, oval cells are considered bipotential because
of their ability to produce both hepatocytic and biliary cell
types in vitro. The cellular origin of oval cells is currently not
known, but it is hypothesized that oval cells are the progeny of
resident adult hepatic stem cells.
Oval cells in the rat are identified primarily by their oval
shape and high nucleus-to-cytoplasm ratio. Interestingly,Figure 1 The current model of hematopoietic stem cells (HSCs) in l
HSCs and liver bile duct epithelium cells (shown with dashed lines th
cells and hepatocytes are derived from an oval cell precursor and t
after activation by Kupffer cells. Adapted from Grompe (2003).phenotypic oval cells have not been found in the developing
fetal rodent liver (Shiojiri et al., 1991). However, cells that
express genes found in oval cells (e.g., α-fetoprotein and
albumin) are present (Shiojiri et al., 1991). This suggests that
there is a stem cell precursor that gives rise to adult oval cells.
Previously, hematopoietic stemcellswere considered tobe the
primary precursor to oval cells, but they no longer are.
It should be emphasized that the term “oval cell” is not
well defined and that “oval cells”may not represent a single
cell type, but a heterogeneous population of immature he-
patic cells. Nonetheless, the factors that stimulate prolifera-
tion and differentiation of hepatic stem cells in response to
liver injury are of interest for the development of cell-based
therapies in liver disease. This knowledge could potentially
be used in two ways: (1) for the targeted differentiation of
embryonic stem cells and (2) for the expansion and dif-
ferentiation of adult hepatic progenitors in large numbers
in culture. Several laboratories have contributed to the
elucidation and identification of the pathways that may
govern the oval cell activation process (Brooling et al., 2005;iver injury is that there is no direct lineage relationship between
at are interrupted by a thick black line). It is accepted that oval
hat most bone marrow-derived hepatocytes originate by fusion
92 L. Erker, M. GrompeKnight et al., 2007; Matthews et al., 2004; Mavier et al., 2004;
Oben et al., 2004; Okaya et al., 2005; Tanimizu et al., 2004;
Yang et al., 2004). These elegant studies, which will be
discussed here, raise the possibility that the growth and
differentiation of hepatic progenitors and oval cells may be
controlled in vitro.
Currently, the molecular mechanisms that lead to oval
cell activation are not well understood. Hepatocyte injury is
involved, but the mechanism(s) by which the damage is
communicated to the oval cell precursors is unknown. Fur-
thermore, the specific roles of various hepatic cell types in
the signaling process are unclear. Therefore, several scenar-
ios for oval cell activation must be considered (Fig. 2):
(1) Oval cell activation could be the result of direct
signaling from damaged hepatocytes to the oval cell
precursors (Fig. 2A).
(2) Oval cells may be activated indirectly by signals from
hepatic stellate cells in response to hepatocyte injury
(Fig. 2B).Figure 2 There are several ways in which oval cells may be
activated after extensive liver injury. Oval cell activation could
be the result of: (A) direct signaling from damaged hepatocytes
to the oval cell precursors, (B) signals initiated by the
hepatocytes through hepatic stellate cells, or (C) multiple cell
types contributing to the activation process: cytokines released
by inflammatory cells (Tcells) at the site of injury may stimulate
oval cell proliferation either directly through the oval cell
precursor or indirectly via stellate cells. Another possibility is
that endothelial cells are the source of a primary signal to the
oval cells through the oval cell precursor.(3) Inflammatory cells may be primarily responsible for
the stimulation of oval cell activation and proliferation
by the release of damage-induced cytokines (Fig. 2C).
(4) Endothelial cells could be the source of the primary
signal (Fig. 2C).
(5) Multiple cell types may be required and each may
contribute to the activation process (Fig. 2C).
Unfortunately, few cell surface markers exist to frac-
tionate viable liver cell subpopulations by fluorescence-
activated cell sorting. Thus, basic knowledge about the size,
location, and morphology of liver stem cells is still lacking.
Nonetheless, partial cell purification has been carried out
using existing surface markers and used to isolate cells for
microarray analysis during the oval cell response. Such gene
expression analysis is beginning to elucidate the pathways in
oval cell activation. In addition, oval cell lines have been
successfully differentiated into hepatocytes and bile ducts in
vitro, thus providing information about lineage decisions in
the liver (Radaeva and Steinberg, 1995). Several groups have
developed novel protocols in rodents for the enrichment and
expansion of intrahepatic stem cells in tissue culture,
demonstrating that the adult liver contains stem cells that
are capable of extensive proliferation (Monga et al., 2001).
The Process of Progenitor-Dependent
Liver Regeneration
Soon after liver injury through one of the mechanisms
mentioned in Table 1 there is an early inflammatory response,
resulting in a surge of cytokine expression. Following this,
cytokine-activated growth factors induce the emerging oval
cells to undergo abundant proliferation and to expand out of
the periportal regions. A separate set of signals activates the
cells to differentiate into either hepatocytes or bile ducts as
they proliferate. The factors that end the oval cell response
are not as well understood. Because of this multistep process
this review has been organized to represent the approximate
order in which these factors appear during the oval cell
response (Fig. 3).
To study the proliferation of oval cells, there are four pro-
tocols commonly used in rodents (Table 1). The four most
commonly used models of oval cell activation are: (1) diet
with added 3-diethoxycarbonyl-1,4-dihydrocollidine (DDC); (2)
choline-deficient,ethionine-supplementeddiet(CDE);(3)treat-
ment with 2-acetylaminofluorene and 70% partial hepatectomy
(2-AAF/PH); and (4) injection with N-acetylparaaminophen.
These models work through different modes of liver injury. For
instance, DDC induces damage by blocking the biosynthesis of
heme (porphyria) in hepatocytes, resulting in the deposition of
porphyrins and leading to the proliferation of periportal
epithelial cells after only 3 days of treatment. After 3 weeks
the reaction reaches its peak (Preisegger et al., 1999). It was
recently found that there are significant differences in the
extents to which these protocols induce oval cell activation
responses in rats and mice (Jelnes et al., 2007). The main
difference was that more fetal genes and proteins were
expressed in rat oval cells than in the mouse. Murine oval cells
are duct-like in morphology (positive for CK19 and A6 but
negative for α-fetoprotein (AFP)), while rat oval cells are
positive for AFP. Thus, rat oval cells resemble fetal hepatoblasts,
Figure 3 A timeline representing the stages of oval cell activation: activation, proliferation,migration, and differentiation. The factors
that are involved in each stage of the response are listed at the bottom.
Table 1 Rodent models of oval cell activation
Oval cell activation regime Rodent
model
Choline-deficient, ethionine-supplemented
diet (Shinozuka et al., 1978)a
Rat and
mouse
Treatment with 2-acetylaminofluorene and
70% partial hepatectomy (Fujio et al.,
1994; Preisegger et al., 1999; Shinozuka
et al., 1978)a
Rata and
mouse
Diet with added 3-diethoxycarbonyl-1,
4-dihydrocollidine (Preisegger et al., 1999)a
Mousea and
rat
Cocaine/phenobarbital (Rosenburg et al., 2000) Mouse
Injection with N-acetylparaaminophen
(Kofman et al., 2005)a
Mouse
Dipin (1,4-bis[N,N'-di(ethylene)phosphamide]
piperazine) injection, followed by partial
hepatectomy (Engelhardt et al., 1990;
Factor et al., 1994)
Mouse and
rat
Galactosamine (Lemire et al., 1991; Lesch
et al., 1970; Medline et al., 1970)
Rat
aCommonly used.
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absenceofAFPexpressionduringoval cell activation inmice is in
the cocaine/phenobarbital model, which activates AFP expres-
sion in cells with duct-like morphology (Cascales et al., 1994;
Evans and Harbison, 1978; Powell et al., 1994; Rosenberg et al.,
2000). These differences aside, all of the protocols were shown
to induce an intense inflammatory response in rodents (Jelnes
et al., 2007).
These activation models have proven to be powerful tools
in identifying the duct-like cells and blood cells that are
present after oval cell activation. However, oval cell
activation remains poorly understood overall and there are
many other periportal nonparenchymal cell types of
unknown potential and function present during progenitor-
dependent liver regeneration.
Cytokines Involved in the Inflammatory Response
After treatment with an oval cell activation protocol, a strong
response occurs, with the infiltration of inflammatory cells
into the liver. With CDE treatment there is a release of two
waves of cytokines, the first at 3 days posttreatment and the
next at 15 days posttreatment (Knight et al., 2005).
Inflammatory cells are known to release cytokines and there
are several lines of evidence suggesting a role for such
cytokines in oval cell activation. Themajority of this evidence
presents a close temporal correlation between liver injury,
cytokine production, and oval cell proliferation (Cassell et al.,1998; Ihrig et al., 1999; Libbrecht et al., 2000; Lowes et al.,
1999; Yin et al., 1999). For instance, the level of interleukin-6
(IL-6), while undetectable in healthy animals, is dramatically
increased with liver damage. Further, immediately following
94 L. Erker, M. Grompeliver injury with CDE treatment, leukocytes transiently
infiltrate the liver. After this, the oval cells begin proliferat-
ing, suggesting a correlation between inflammation, cytokine
production, and oval cell activation (Knight et al., 2005).
IL-6 family cytokines
This family of cytokines, which includes IL-6, leukemia
inhibitory factor (LIF), and oncostatin M (OSM), is distin-
guished by their ability to signal through the transducing
receptor molecule glycoprotein 130 (gp130), ultimately
activating the Janus kinase/signal transducers and activators
of transcription (JAK/STAT) pathway (Kishimoto et al., 1995;
Taga and Kishimoto, 1997; Yamasaki et al., 1988). The effects
of this pathway will be discussed below.
Leukemia inhibitory factor (LIF)
LIF is sonamed for its ability to terminally differentiatemyeloid
leukemia cells. This IL-6 family cytokine is involved in many
cellular processes, including cellular proliferation, differentia-
tion, and inflammation. There is increased expression of LIF in
spindle-shaped myofibroblasts (activated stellate cells) of
cirrhotic liver (Lowes et al., 2003b). There is no LIF receptor
β (LIFRβ) inmyofibroblasts themselves, suggesting that there is
a paracrine effect of LIF from myofibroblasts on other cells in
the liver (Gressner, 1996). LIFRβ and gp130 mRNAs are
expressed in oval cells and parenchymal cells (Omori et al.,
1996), further suggesting a role for LIF in oval cell activation.
Onocostatin M (OSM)
This IL-6 family cytokine is involved in activating, as well as
inhibiting, proliferation in many different cell types. It is
involved in inflammatory responses, remodeling of extra-
cellular matrix, hematopoiesis, and modulation of cell
growth and differentiation. Specifically in the liver, two
groups have shown that OSM is important in hepatocyte
differentiation. Initially, Matsui et al. (2002) demonstrated
that OSM causes fetal hepatocytes to differentiate into
mature hepatocytes in an in vitro culture system. Then
Okaya et al. (2005) showed that OSM treatment induces the
rat oval cell line OC15-5 to differentiate into hepatocytes.
Further, when rat oval cells were incubated in medium from
293 cells expressing rat OSM cDNA there was growth
suppression along with changes in morphology in which
microvilli appeared and a large cytoplasm developed with
organelles, as well as the expression of hepatocyte markers
like albumin, tyrosine aminotransferase, and tryptophan
oxygenase (Okaya et al., 2005). They also found that there
was a linear relationship between OSM-R expression and the
number of oval cells in rat liver undergoing regeneration
from AAF/PH and that OSM-R expression was exclusively
found in oval cells (Okaya et al., 2005). These results
indicate that OSM is a mediator for inducing differentiation
of fetal hepatocytes and OC15-5 rat oval cell lines into
mature hepatocytes. Thus, OSM and OSM-R are important
factors for the differentiation of oval cells to hepatocytes
during liver regeneration. OSM is secreted by Kupffer cells,
highlighting the possible role of these cells in oval cell
activation. Cells receive the OSM signal through OSMreceptor-β (OSMRβ) and LIFRβ. As mentioned above, OSM
signals through cell surface receptors that contain the gp130
protein. OSM binds to either the type I receptor, composed of
gp130 and LIFRβ, or the type II receptor, which is composed
of gp130 and OSMRβ.
These receptors are expressed in both normal and
cirrhotic liver. However, LIFRβ expression is markedly
increased in cirrhotic liver. The LIFRβ-expressing cells are
epithelial bile duct cells that are positive for cytokeratin 7,
proliferating cell nuclear antigen, and LIF (Znoyko et al.,
2005), suggesting that OSMmay preferentially signal oval cell
activation through LIFRβ. A comprehensive review on OSM
was done by Tanaka and Miyajima (2003).
Interleukin-6 (IL-6)
IL-6 is well recognized as an important regulator of the
hepatic injury response. This has been shown in both
experimental and clinical settings; for a comprehensive
review please see Streetz et al. (2001). Mice treated with the
CDE diet have elevated levels of IL-6 and knockout mice show
a reduction in the number of oval cells when treated with the
same regimen (Knight et al., 2000; Yeoh et al., 2007). In
contrast to this, Rosenberg et al. (2000) demonstrated that
IL-6 is not required for liver regeneration after cocaine/
phenobarbital treatment, since IL-6 knockout mice under-
went liver regeneration in the same length of time as wild-
type mice. However, it is difficult to compare these studies
because the former used a conditional knockout of the
negative regulator of IL-6, suppressor of cytokine signaling,
and transgenics with an overactive STAT3 protein, while the
latter used IL-6-deficient mice. Thus, one was studying the
direct effect of IL-6 loss and the other was looking at the loss
of an IL-6 suppressor and increased STAT3 signaling.
JAK/STAT pathway
Downstream of IL-6, OSM, LIF, and interferon-γ (IFN-γ) are
transcription factors that activate the proliferation of oval
cells, such as the STAT family genes. Activation via IL-6, LIF,
or OSM involves dimerization with gp130, while IL-6 signaling
through the IL-6 receptor involves the formation of a gp130
homodimer (Murakami et al., 1993). LIF signaling involves
the formation of a gp130/LIFRβ heterodimer (Davis et al.,
1993; Pennica et al., 1995). OSM signals through the LIFRβ or
the OSMRβ to form gp130 heterodimers (Gearing et al., 1992;
Znoyko et al., 2005). gp130 transduces the signal by
interacting with downstream tyrosine kinases, the JAK tyro-
sine kinase family members. These kinases phosphorylate
gp130, providing docking bays for the cytoplasmic STAT pro-
teins. Once the STAT proteins have docked and been phos-
phorylated they translocate to the nucleus to regulate the
transcription of STAT family genes. Thus, it is not surprising
that there is evidence that STAT3 is involved in the oval cell
response. Some good reviews on STAT signaling have been
published (Brivanlou and Darnell, 2002; Heinrich et al., 2003;
Levy and Darnell, 2002; O'Shea et al., 2002). Knock-in mouse
models have demonstrated that hyperactive STAT3 signaling
results in enhanced oval cell numbers, whereas extracellu-
lar-regulated kinase activation suppresses oval cell pro-
liferation (Yeoh et al., 2007). Also, evidence suggests that
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(Sanchez et al., 2004).
IFN-γ activates the JAK/STAT through another mode by
binding of the IFN-γ homodimer to interferon-γ receptor I
(IFNGR1), which results in dimerization of IFNGR1/IFNGR2
complexes. This leads to transphosphorylation and activation
of the JAK kinases. Phosphorylation of a tyrosine in IFNGR1
creates a docking site for the SH2 domain of the STAT1
transcription factor, which is then phosphorylated by the JAK
kinases. Phosphorylated STAT1 dissociates from the receptor
complex, homodimerizes, and translocates into the nucleus.
STAT1 binds to the interferon-γ activated sequence promoter
element, which leads to an increased expression of inter-
feron-stimulated genes, ultimately modulating the IFN-γ
signal (Darnell et al., 1994; Stark et al., 1998).
Interferon-α(IFN-α)
IFN-α also acts through STAT3 phosphorylation. However, it
has the opposite effect compared to the other STAT3-
activating IL-6 family members (IFN-γ and IL-6/OSM),
reducing oval cell proliferation and increasing apoptosis in
oval cell lines (Lim et al., 2006). It is currently not understood
how IFN-α and IL-6/OSM both act through STAT3 but have such
differing effects on oval cell growth.
Interleukin-18 (IL-18)
IL-18 is a cytokine that activates natural killer cells and
certain T cells to release IFN-γ. IL-18 expression is rapidly
induced in mice after only 2 days of CDE treatment (Knight
et al., 2005). As such, this cytokine is involved in the early
inflammatory response that induces a signaling cascade that
includes IFN-γ secretion.
Interferon-γ (IFN-γ)
IFN-γ is a soluble cytokine secreted solely by T lymphocytes
and natural killer cells. This is in contrast to IFN-α and IFN-β,
which are expressed ubiquitously. Several lines of evidence
demonstrate the importance of IFN-γ in oval cell activation.
IFN-γ-deficient mice have an attenuated oval cell response,
while liver regeneration after partial hepatectomy is
enhanced (Akhurst et al., 2005; Sun and Gao, 2004). Thus,
increased expression of IFN-γ and its target genes is specific
to oval cell activation and not progenitor-independent
regeneration (e.g., regeneration after partial hepatectomy)
(Akhurst et al., 2005; Bisgaard et al., 1999; Knight et al.,
2000; Lowes et al., 2003b). Further, IFN-γ in conjunction
with tumor necrosis factor (TNF) and lipopolysaccharide,
which are both present during liver growth, causes cell cycle
arrest in cultured hepatocytes while activating oval cell
growth (Brooling et al., 2005). This differential effect on
hepatocytes and oval cells represents one of the few factors
that elicit a differential response in these cells.
Lymphotoxin-β (LT-β)
LT-β has an important role in inflammation since it is also
implicated in oval cell activation. It is a likely target of
proinflammatory cytokines because its promoter contains afunctional nuclear factor-κB (NF-κB) element. Further, it is
activated by IL-6 and IL-1β (Lowes et al., 2003a; Subrata et al.,
2005). LT-β is expressed in oval cells during oval cell-mediated
liver regeneration induced by chronic hepatitis (Lowes et al.,
2003b). LT-β is found on hepatocytes, oval cells, and
inflammatory cells. Its receptor, LT-βR, is a member of the
TNFR (tumor necrosis factor receptor) superfamily.
Stem cell factor (SCF)
SCF is a growth factor that is involved in the survival,
proliferation, differentiation, and migration of a variety of
stem cells (Galli et al., 1994). There is evidence that SCF is
involved in progenitor-dependent liver regeneration since it
is induced early in progenitor-dependent regeneration via 2-
AAF/PH in rats but not with PH alone (Fujio et al., 1994). Also,
SCF is a cell-surface-bound cytokine that is cleaved by
metalloproteases and released to bind to the c-kit receptor,
which was demonstrated to be restricted to oval cells (Fujio
et al., 1994; Galli et al., 1994). Further evidence for c-kit
involvement in oval cell activation was found in the Ws/Ws
rats, which have severely impaired c-kit receptor kinase
activity, in which oval cells were slow to appear after liver
damage (Matsusaka et al., 1999). However, c-kit-knockout
cells expressed similar oval cell proteins and had similar
growth rates (based on thymidine and Ki-67 labeling) com-
pared to wild-type controls (Matsusaka et al., 1999). This
suggests that, while the SCF/KIT pathway plays an important
role in the development of oval cells, in the 2-AAF/PH rat
model it has little effect on the proliferative activity and
gene expression of these cells.
Stromal cell-derived factor-1α (SDF-1)
SDF-1α is a small cytokine, or chemokine, that is officially
designated chemokine (C-X-C motif) ligand 12 (CXCL12). This
factor signals through its unique receptor CXCR4, which is also
knownas fusin (Bleul et al., 1996; Sweeneyet al., 2002). CXCR4
is expressed by most leukocytes as well as endothelial cells
(Luster, 1998; Murdoch and Finn, 2003) and has been shown to
act as a migration factor in hematopoiesis (Peled et al., 1999).
SDF-1 is upregulated during progenitor-dependent liver regen-
eration in rats (Hatch et al., 2002), and knockdown of SDF-1 in
mice results in attenuated hepatocyte proliferation after
damage and reduces expression of oval cell markers OV6 and
AFP (Zheng et al., 2006). SDF-1 was expressed after 2-AAF/PH
in hepatocytes (Hatch et al., 2002), while its receptor, CXCR4,
was found on oval cells (Hatch et al., 2002;Mavier et al., 2004).
Another group also demonstrated that SDF-1 was expressed
mainly in hepatocytes located in the pericentral region of the
liver (Zheng et al., 2006). This contradicts work done by Mavier
et al. in 2004, inwhich they showed that only oval cells, and not
hepatocytes, expressed SDF-1 (Sweeney et al., 2002). This
discrepancy may be due to a difference in antibodies between
the two studies.
These data suggest that SDF-1 acts through both a
paracrine and an autocrine mechanism to activate oval cell
migration. This is because in vitro chemotaxis assays demon-
strated that oval cells migrate along a SDF-1 gradient,
suggesting that its function in liver regeneration is to direct
cell migration (Hatch et al., 2002) and thus providing a
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introduce them into an environment that favors their
proliferation and differentiation. Further evidence that SDF-
1/CXCR4 is involved in cell migration was found by McGrath
et al. (1999), whereby expression correlatedwithmigration as
early as gastrulation. Further, migration assays demonstrated
a dependence on an SDF-1 gradient.
Tumor Necrosis Factor (TNF)
Once the inflammatory cells arrive at the site of liver injury
there must be other factors to stimulate them to release
cytokines. One cell type that may release such factors is the
Kupffer cell, since during liver regeneration they release the
majority of TNF in the liver (Olynyk et al., 1998). TNF
activates TNFR1 on inflammatory cells to release several
cytokines via NF-κB (Auphan et al., 1995). After the oval cells
receive this signal, there is an autocrine effect whereby they
also release TNF. TNF release by oval cells also stimulates
inflammatory cells, which express TNFR1, to produce
cytokines (Knight et al., 2000). Further evidence that TNF
is involved in oval cell activation is that TNFR1 knockout mice
have a clearly impaired oval cell response, while TNFR2-
deficient mice have normal oval cell induction (Knight et al.,
2000). Activation of this pathway also causes increased
vascular permeability, anticoagulant activity, and leukocyte
adhesion. In neutrophils TNF activates the respiratory burst
and degranulation leading to the release of reactive oxygen
species and proteolytic enzymes such as elastase. TNF also
participates in the apoptotic process. This demonstrates that
the TNF pathway is involved in activating cytokine release as
well as inducing apoptosis in damaged cells.
TNF-like weak inducer of apoptosis (TWEAK)
TNF-like weak inducer of apoptosis is part of the TNF family of
growth regulators and has weak apoptotic activity for some
human tumor cell lines (Wiley et al., 2001; Wiley andWinkles,
2003). This multifunctional cytokine binds to the Fn14
receptor, which is a member of the TNF receptor family
(Feng et al., 2000; Wiley et al., 2001). Recently, it was
demonstrated that TWEAK is involved in hepatic progenitor
cell proliferation. Transgenicmice expressing TWEAK from the
liver-specific α1-anti-trypsin promoter displayed periportal
oval cell hyperplasia. Further, this mitogenic effect was
mediated through Fn14 since Fn14-null mice demonstrated a
significantly reduced oval cell response after DDC treatment
(Jakubowski et al., 2005). This represents the first factor that
selectively activates oval cell proliferation while having no
mitogenic effect on hepatocytes (Jakubowski et al., 2005).
Paracrine Growth Factors Released by Hepatic
Stellate Cells
Stellate cells can regulate oval cell function by releasing
growth factors. Some of the effects of these growth factors are
not well understood; they appear to have both proliferative
and antiproliferative activities for oval cells. This is thought to
be related to the context in which the signal is received, since
oval cells must remain quiescent during progenitor-indepen-
dent liver regeneration and be activated only when hepato-cytes have been so extensively injured that they cannot
proliferate. Thus, the oval cell precursors do not respond to
growth factors in one context (progenitor-independent regen-
eration) but may in another (e.g. progenitor-dependent
regeneration). It is still not understood how these various
signals are successfully interpreted by oval cells.
Transforming growth factor-α (TGF-α)
TGF-α is increased in hepatic stellate cells and oval cells of
the 2-AAF/PH model (Evarts et al., 1992, 1993). However,
Okano et al. (2003) have reported that there are no TGF-α
receptors or epidermal growth factor receptors found on the
rat oval cell line OC/CDE22. If it is the case that oval cells
express TGF-α, but do not respond to it, then they may be
using it to signal other cells in a paracrine fashion. It has been
shown that TGF-α expression is increased only 12 h post-2-
AAF/PH treatment (Evarts et al., 1993), demonstrating a role
for this molecule in oval cell activation that may not
necessarily be directly through oval cells themselves.
Transforming growth factor-β (TGF-β)
Hepatic stellate cells express TGF-β and this expression
coincides with oval cell proliferation in the 2-AAF/PH model
(Park and Suh, 1999). TGF-β is downstream of TNF, which
activates the release of cytokines. Opposing roles for TGF-β in
the oval cell response have been described. Nguyen et al.
(2007) published work in oval cell lines suggesting that oval
cells are less responsive to TGF-β suppression and could
proliferate in the presence of this signal. They demonstrated
that phospho-Smad2, which is downstream of TGF-β, was
reduced in oval cells of CDE-treatedmice (Nguyenet al., 2007).
Increased phospho-Smad2 in hepatocytes directly correlated
with reduced Ki67 labeling, suggesting a lower rate of
proliferation. The opposite was found for oval cells in the
same tissue, which showed an inverse relationship between
phospho-Smad2 and proliferation (Nguyen et al., 2007). This
finding demonstrates how oval cells may be able to remain
quiescent in the face of progenitor-independent growth, yet
proliferate and differentiate rapidly when hepatocytes cannot
divide. Conversely, TGF-β overexpression in vivo, with an
albumin promoter (thought to be exclusively expressed in
hepatocytes), negated an oval cell response after DDC
treatment in mice (Preisegger et al., 1999). This result was
interpreted to suggest that TGF-β expression inhibits the oval
cell response. However, since both hepatocytes and a subset of
oval cells express albumin it is possible that overexpression of
this growth factor in oval cells inhibited their proliferation.
Hepatocyte growth factor (HGF)
Since elevated serum HGF levels have been found in people
with chronic hepatitis and cirrhosis of the liver, a potential
role is suggested for this factor in oval cell activation
(Nishizaki et al., 1995; Shiota et al., 1995; Tomiya et al.,
1992). HGF expression is increased in proliferating cells after
2-AAF/PH (Evarts et al., 1993). It was also reported that HGF
accelerates oval cell proliferation in this same model (Shiota
et al., 2000). HGF is expressed by hepatic stellate cells that
are proliferating in close proximity to oval cells during liver
97Signaling networks in oval cell activationregeneration (Imai et al., 1996). Interestingly, oval cells do
not express HGF, but only its receptor c-Met (Hu et al., 1996).
As such, HGFmay have a paracrine effect on oval cells via the
HGF receptor (c-Met), sending a proliferation signal (Imai
et al., 1996). It has also been demonstrated that HGF-
induced proliferation exerts its effect through the phospha-
tidylinositol 3-kinase/AKT pathway (Okano et al., 2003).
Fibroblast growth factor-1 (FGF-1)
FGF-1 is expressed by oval cells, basophilic hepatocytes, and
hepatic stellate cells in the liver (Lowes et al., 2003b). This
factor is also known as acidic fibroblast growth factor (aFGF)
and heparin-binding growth factor type I. At the peak of oval
cell activation there is an increase in FGF-1 in the 2-AAF/PH
model (Hu et al., 1996). FGF-1 expression increases 24 h
after PH (pretreated with 2-AAF). It is interesting that this is
12 h after TGF-α and HGF expression is induced by the same
stimulus (Evarts et al., 1993). This suggests that it may serve
some other function beyond purely inducing proliferation, as
TGF-α and HGF have been shown to do.Figure 4 Oval cells are activatedby factors that are secretedbymany
their particular cell type(s). From this figure one can get a sense of the cEpidermal growth factor (EGF)
The contradictory results reported regarding EGF warrant its
mention in this review. While early work demonstrated that
EGF could stimulate proliferation of oval cell lines on soft
agar (Braun et al., 1989), another group found that there was
no EGFR on oval cells (Okano et al., 2003). The real role for
EGF, if any, in oval cell activation remains unknown.
Delta-like protein/preadipocyte factor-1 (Dlk/Pref-1)
Dlk/Pref-1 is a transmembrane receptor that has six EGF-like
repeats in its extracellular domain. Dlk/Pref-1 is expressed on
hepatoblasts in the mouse fetal liver and in rodents dur-
ing progenitor-dependent liver regeneration (Jelnes et al.,
2007; Tanimizu et al., 2003). In fact, it is expressed in most of
the common models of oval cell activation: CDE, DDC, and 2-
AAF/PH treatment (Jelnes et al., 2007). Dlk+cells represent a
subpopulation of oval cells that are 20% CK19+, proliferate
more slowly than other oval cells, are distant from periportalcells in the liver. Factors thatwerediscussedhere are shownnext to
omplexity of the signaling network involved in oval cell activation.
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hepatocytes (Tanimizu et al., 2004), suggesting that these
cells may represent intermediate cells between Dlk− oval cells
and mature hepatocytes.
Extracellular Matrix Remodeling: Plasmin
Activator and Plasmin Proteolytic Cascades
As the oval cells proliferate in the periportal zone they must
move into the surrounding tissue, differentiate, and provide
ample space for the new cells to reside. This involves extensive
tissue remodeling. The plasminogen activator/plasmin pro-
teolytic cascades are involved in thrombolysis and extracel-
lular matrix remodeling. There has been a link made between
stemcell proliferation and changes in the extracellularmatrix.
It is hypothesized that these proteins play a role during oval
cell proliferation that allows the proper structural changes to
take place to accommodate the new cells that are produced to
regenerate the liver (Kim et al., 1997). This plasmin system is
complex and involves many proteins, including urokinase-type
plasminogen activator (uPA), tissue-type plasminogen activa-Table 2 Summary of factors involved in the oval cell response
Activation Proliferation M
Cytokines
LIF +
OSM/OSM-R −
IL-6 + +
JAK/STAT +
IFN-α −
IL-18 +
IFN-γ +
LT-β +
SCF/c-kit + +
SDF-1/CXCR4 +
TNF receptor cytokines
TNF +
TWEAK +
Paracrine growth factors
TGF-α +
TGF-β −
HGF +
FGF-1 +
EGF (role unknown)
Dlk/Pref-1
ECM remodeling
uPA +
tPA +
uPAR +
PAI-1 +
Cox-2 (role unknown)
Sympathetic nervous system +(hypothesized)
The far right column describes the transgenic mouse that was used to
obtained using in vitro methods.tor (tPA), the uPA receptor (uPAR), and plasminogen activator
inhibitor 1 (PAI-1).
There is evidence that this system is involvedduringboth liver
regeneration and oval cell activation. First, uPA mRNA is
increased with oval cell proliferation, and infusion of uPA en-
hanced growth of cells in the periportal regions after 2-AAF
treatment (Bisgaardet al., 1999). Also, uPAexpressionwas found
in nonparenchymal cells along the hepatic sinusoids (Bisgaard
et al., 1998). Beyond regulating the infiltration of proliferating
oval cells and liver remodeling during regeneration, this system
may also impact the activity of several growth factors that
are involved in oval cell activation. For instance, both HGF and
TGF-αmust be activated by proteolytic cleavage after secretion
by hepatic stellate cells (Mars et al., 1993; Miyazawa et al.,
1994). Further, the expression of uPA, uPAR, and PAI-1 is re-
gulated by several cytokines and growth factors including HGF,
EGF, and TGF-β (Naldini et al., 1991; Taipale et al., 1992).
Cyclooxygenase-2 (Cox-2)
Cyclooxygenase enzyme (Cox-2) appears to be involved in
oval cell activation: (1) it responds to cytokines; (2) it isigration Differentiation Transgenic mouse
+
+
Knockout
Transgenic
Knockout
Ws/Ws rat
Knockout
Fn14 knockout; TWEAK transgenic
Transgenic
+
find the listed results. Unless otherwise stated, the results were
99Signaling networks in oval cell activationexpressed by rat Kupffer cells; (3) its expression is increased
in chronic hepatitis, cirrhosis, and hepatocellular carcinoma;
and (4) it is expressed in nonparenchymal cells during hepa-
tocarcinogenesis (Koga et al., 1999; Kondo et al., 1999; Souto
et al., 2001). Cox-2 is responsible for converting arachidonic
acid into a number of different prostaglandins that have
effects on inflammation and carcinogenesis. Blocking Cox-2
with SC236 inhibitor reduced the number of CDE-diet-
induced pathologies in mice (Davies et al., 2006). The
inhibitor studies suggest that Cox-2 would have an anti-
apoptotic effect or activate proliferation. However, it is not
understood how this enzyme activates oval cells, and further
expression studies need to be done to determine what the
effect of Cox-2 is on oval cells in vivo.
Involvement of the Sympathetic Nervous
System (SNS) in Oval Cell Activation
There is evidence that the SNS is involved in liver fibrosis. SNS
inhibitors reduce liver fibrosis, and SNS overactivation, in the
rat, results in unusually severe liver fibrosis after treatment
with hepatotoxins (Hsu, 1992, 1995). Evidence suggests that
the hepatic stellate cells are the targets of SNS stimulation
(Oben et al., 2004). Since stellate cells are responsible for
fibrotic collagendeposition following liver damage and the SNS
activates these cells, they are the most probable target of the
SNS. Using dopamine β-hydroxylase-deficient mice (Dbh−/−),
which cannot make the SNS neurotransmitter norepinephrine,
it was shown that injury-induced fibrogenesis was significantly
reduced compared to wild-type mice (Oben et al., 2004).
Hepatic stellate cells are thought to signal the presence of
damage and play a role in oval cell activation. As such, this
would follow the hypothesis that the SNS stimulates hepatic
stellate cell activation, which then plays a role in stimulating
an oval cell response after extensive liver damage.
Summary
In this review we have described the factors that have been
reported to be involved in oval cell activation, migration,
and differentiation. Producing an integrated scheme regard-
ing the timeline for when these factors are made, which cell
types produce ligands, and which their receptors, as well as
their precise functions, remains a challenge to the field. A
few definitive themes are beginning to emerge. We do know
that inflammatory cytokines play a primary role in oval cell
activation, inducing growth factor expression. Activated
stellate cells are always present and produce crucial com-
ponents of the response. As the oval cells proliferate, mi-
grate, and differentiate, a set of new factors, like plasmin
activator and the plasmin proteolytic cascades, allows for
tissue remodeling. Fig. 4 represents a summary of the cu-
rrent knowledge regarding the interplay of cell types and
factors involved in the oval cell response. It should be noted
that the literature surveyed for this review is rather het-
erogeneous and contains reports from different species
(mouse, rat, human), different injury models (DDC, CDE,
etc.), and in vivo and in vitro experiments. Thus, different
and sometimes seemingly contradictory data regarding the
function of a specific factor can be found. We consider
in vivo genetic data obtained with knockout and transgenicmice to be most conclusive in terms of proving a definitive
role for a particular protein in the oval cell response (see
Table 2 for a summary).
Progenitor-dependent liver regeneration is an important
process with significance for human liver disease, carcino-
genesis, and regenerative medicine. Much additional work is
needed to understand this process fully, but overall progress
has been encouraging. This raises the hope that intrahepatic
stem cells will be amenable to therapeutic manipulations in
the not too distant future.
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